Faron Pharmaceuticals OY (FARN) NPV
No change
- Add to watchlist
- Create an alert
- This stock can be held in a
No change
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
No change
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
235.00p
230.00p
485.00p
£125.10 million
235.00p
230.00p
215.00p
n/a
0.00p (0.00%) Previous:
0.00p
3,000
n/a
5,000
Performance
Not available for this stock.
Fundamental data
| Year ending: | 31/12/2021 | 31/12/2020 |
|---|---|---|
| Revenue (€m) | n/a | n/a |
| Profit before tax (€m) | (21.18) | (16.93) |
| Adjusted EPS (¢): | (42.00) | (37.00) |
| P/E ratio | n/a | n/a |
| PEG | n/a | n/a |
| EPS growth (%) | n/a | n/a |
Values are quoted in the stock's local currency: Euro
All fundamental dataDividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
To buy shares in , you'll need to have an account.
Try our handy filter to explore the different options.
Ready to invest?
To invest in , you'll need to open an account.
Try our handy filter to find which one suits you best.
Important Documents
There are no documents available for this stock.
Broker forecasts
Due to changes in how we source investment data, Broker Forecasts are not available. We're sorry for any inconvenience this may cause.
-
Faron upbeat on updated data from cancer treatment study
23 February 2022 13:37
-
Marie-Louise Fjallskog tapped as Faron's new chief medical officer
4 January 2022 16:10
-
Faron Pharmaceuticals wins dispute with Rentschler at tribunal
9 November 2021 11:23
-
FDA and FIMEA approve BEXMAB study to begin
16 May 2022 07:00
-
Ex Vivo Data Presented at EHA2022 Congress
12 May 2022 15:50
-
Mol Cancer Ther Publishes Bexmarilimab Research
9 May 2022 07:00
Recent trade data is unavailable. We will be replacing it, however in the meantime the information is available on the London Stock Exchange website.
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.